journal article·2013-01-22

Markedly Enhanced Permeability and Retention Effects Induced by Photo-immunotherapy of Tumors

Kohei Sano, Takahito Nakajima, Peter L. Choyke, Hisataka Kobayashi

ACS Nano· Volume 7· Issue 1
Publisher page

Abstract

A major barrier to cancer treatment is the inability to deliver sufficient concentrations of drug to the tumor without incurring systemic toxicities. Nanomaterials are appealing because they can carry a large drug payload; however, tumor delivery is limited by modest leakage and retention in most tumors. We observed that after photoimmunotherapy (PIT), which is a light-mediated treatment based on an antibody-photosensitizer conjugate, there was surprisingly high leakage of nanosized (10-200 nm) agents into the tumor bed. PIT rapidly induced death in perivascular cancer cells, leading to immediate and dramatic increases in vascular permeability, resulting in up to 24-fold greater accumulation of nanomaterials within the PIT-treated tumor compared with controls, an effect termed "super-enhanced permeability and retention". In a treatment study, PIT followed by liposome-containing daunorubicin, DaunoXome (diameter 50 nm), resulted in greater survival in tumor-bearing mice than either PIT or DaunoXome alone. Thus, PIT greatly enhances delivery of nanosized reagents and thus holds promise to improve therapeutic responses.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1088, United States

References (26)

Show source-provided references
1. Minchinton A. I. · Nat. Rev. Cancer · 2006 · 6 · 58310.1038/nrc1893 ↗
2. Hambley T. W. · Cancer Res. · 2009 · 69 · 125910.1158/0008-5472.CAN-08-3786 ↗
3. Peer D. · Nat. Nanotechnol. · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
4. Maeda H. · Bioconjugate Chem. · 2010 · 21 · 79710.1021/bc100070g ↗
5. Maeda H. · Adv. Drug Delivery Rev. · 2011 · 63 · 12910.1016/j.addr.2010.05.001 ↗
6. Vicent M. J. · Trends Biotechnol. · 2006 · 24 · 3910.1016/j.tibtech.2005.11.006 ↗
7. Jain R. K. · Nat. Med. · 1998 · 4 · 65510.1038/nm0698-655 ↗
9. Forssen E. A. · Cancer Res. · 1992 · 52 · 3255
10. Presant C. A. · Lancet · 1993 · 341 · 124210.1016/0140-6736(93)91147-E ↗
11. Mitsunaga M. · Nat. Med. · 2011 · 17 · 168510.1038/nm.2554 ↗
12. Giusti R. M. · Clin. Cancer Res. · 2008 · 14 · 129610.1158/1078-0432.CCR-07-1354 ↗
13. Waldmann T. A. · Nat. Med. · 2003 · 9 · 26910.1038/nm0303-269 ↗
14. Reichert J. M. · Nat. Biotechnol. · 2005 · 23 · 107310.1038/nbt0905-1073 ↗
15. Weinstein J. N. · Ann. N.Y. Acad. Sci. · 1987 · 507 · 19910.1111/j.1749-6632.1987.tb45802.x ↗
16. Weinstein J. N. · Cancer Res. · 1992 · 52 · 2747s
17. Weissleder R. · AJR Am. J. Roentgenol. · 1989 · 152 · 16710.2214/ajr.152.1.167 ↗
18. Kobayashi H. · Adv. Drug Delivery Rev. · 2005 · 57 · 227110.1016/j.addr.2005.09.016 ↗
19. Clarke S. E. · Radiology · 2000 · 214 · 78710.1148/radiology.214.3.r00mr25787 ↗
20. Seki T. · Cancer Sci. · 2009 · 100 · 242610.1111/j.1349-7006.2009.01323.x ↗
21. Maeda H. · J. Controlled Release · 2010 · 142 · 29610.1016/j.jconrel.2010.01.002 ↗
22. Maeda H. · J. Controlled Release · 2012 · 164 · 13810.1016/j.jconrel.2012.04.038 ↗
23. Suzuki M. · J. Natl. Cancer Inst. · 1981 · 67 · 663
24. El-Sayed I. H. · Cancer Lett. · 2006 · 239 · 12910.1016/j.canlet.2005.07.035 ↗
25. Gormley A. J. · Nano Today · 2012 · 7 · 15810.1016/j.nantod.2012.04.002 ↗
26. Euhus D. M. · J. Surg. Oncol. · 1986 · 31 · 22910.1002/jso.2930310402 ↗